Cygnal Therapeutics Inc., a Cambridge, Mass.-based startup devoted to developing new cancer and immunotherapy drugs, has raised $65 million from Flagship Pioneering to advance research in a field it is calling "exoneural biology" in an effort to deliver relief via the peripheral nervous system. The company is led by Pearl Huang, a veteran of Roche Holding AG and Glaxosmithkline plc. Calling exoneural biology "a new way to look at something that has always been there," she said Cygnal's platform has uncovered "new drivers of disease that are both profound and actionable."